The source of MHC class I presented peptides and its implications

Area of Science:

• Immunology
• Molecular Biology
• Cellular Biology

Background:

• The origin of peptides presented by major histocompatibility class I (MHCI) molecules has been a long-standing question in immunology.
• Traditionally, peptides were thought to derive solely from the degradation of full-length proteins.
• Recent evidence suggests alternative translation products also contribute peptides to the MHCI pathway.

Purpose of the Study:

• To provide an updated overview of peptide sources for the MHCI pathway.
• To integrate findings on alternative mRNA translation products into current models of antigen presentation.
• To stimulate new hypotheses regarding the physiological roles of diverse peptide sources.

Main Methods:

• Literature review and synthesis of existing scientific data.
• Analysis of models for direct and cross-presentation pathways.
• Discussion of experimental evidence supporting alternative translation products as peptide sources.

Main Results:

• The degradation of full-length proteins is not the sole source of peptides for MHCI presentation.
• Alternative translation products, arising from non-canonical mRNA translation, are validated sources of MHCI-presented peptides.
• These findings necessitate a re-evaluation of antigen processing and presentation mechanisms.

Conclusions:

• The MHCI pathway utilizes peptides from both canonical protein degradation and alternative translation products.
• Understanding these diverse peptide sources is crucial for comprehending immune surveillance and response.
• Further research is needed to elucidate the full physiological implications of alternative peptide sourcing.